Genelux (GNLX) Competitors $3.54 -0.02 (-0.56%) Closing price 04:00 PM EasternExtended Trading$3.60 +0.06 (+1.55%) As of 04:44 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock GNLX vs. PRME, ARVN, ETON, SVRA, PVLA, ITOS, SNDL, CGEM, CMPS, and KODShould you be buying Genelux stock or one of its competitors? The main competitors of Genelux include Prime Medicine (PRME), Arvinas (ARVN), Eton Pharmaceuticals (ETON), Savara (SVRA), Palvella Therapeutics (PVLA), iTeos Therapeutics (ITOS), SNDL (SNDL), Cullinan Therapeutics (CGEM), COMPASS Pathways (CMPS), and Kodiak Sciences (KOD). These companies are all part of the "pharmaceutical products" industry. Genelux vs. Its Competitors Prime Medicine Arvinas Eton Pharmaceuticals Savara Palvella Therapeutics iTeos Therapeutics SNDL Cullinan Therapeutics COMPASS Pathways Kodiak Sciences Genelux (NASDAQ:GNLX) and Prime Medicine (NYSE:PRME) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, valuation, earnings, profitability, analyst recommendations, dividends, media sentiment and risk. Does the media favor GNLX or PRME? In the previous week, Prime Medicine had 4 more articles in the media than Genelux. MarketBeat recorded 9 mentions for Prime Medicine and 5 mentions for Genelux. Prime Medicine's average media sentiment score of 0.10 beat Genelux's score of -0.02 indicating that Prime Medicine is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Genelux 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Prime Medicine 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Is GNLX or PRME more profitable? Genelux's return on equity of -107.47% beat Prime Medicine's return on equity.Company Net Margins Return on Equity Return on Assets GeneluxN/A -107.47% -83.14% Prime Medicine N/A -107.87%-74.97% Which has more risk & volatility, GNLX or PRME? Genelux has a beta of -0.32, meaning that its share price is 132% less volatile than the S&P 500. Comparatively, Prime Medicine has a beta of 2.39, meaning that its share price is 139% more volatile than the S&P 500. Do analysts recommend GNLX or PRME? Genelux presently has a consensus target price of $17.75, suggesting a potential upside of 401.41%. Prime Medicine has a consensus target price of $8.92, suggesting a potential upside of 154.76%. Given Genelux's stronger consensus rating and higher possible upside, research analysts clearly believe Genelux is more favorable than Prime Medicine.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Genelux 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 3.20Prime Medicine 0 Sell rating(s) 3 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 2.75 Do institutionals & insiders hold more shares of GNLX or PRME? 37.3% of Genelux shares are owned by institutional investors. Comparatively, 70.4% of Prime Medicine shares are owned by institutional investors. 8.8% of Genelux shares are owned by company insiders. Comparatively, 22.7% of Prime Medicine shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth. Which has preferable earnings and valuation, GNLX or PRME? Genelux has higher earnings, but lower revenue than Prime Medicine. Genelux is trading at a lower price-to-earnings ratio than Prime Medicine, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioGenelux$10K13,370.58-$29.87M-$0.86-4.12Prime Medicine$4.96M94.94-$198.13M-$1.56-2.24 SummaryPrime Medicine beats Genelux on 8 of the 14 factors compared between the two stocks. Get Genelux News Delivered to You Automatically Sign up to receive the latest news and ratings for GNLX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding GNLX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart GNLX vs. The Competition Export to ExcelMetricGeneluxMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$133.71M$3.12B$5.70B$9.79BDividend YieldN/A2.21%3.77%4.10%P/E Ratio-4.1220.7930.8625.27Price / Sales13,370.58232.09403.8888.61Price / CashN/A41.5625.2228.45Price / Book4.669.749.516.00Net Income-$29.87M-$54.74M$3.26B$265.34M7 Day Performance7.93%8.13%4.50%2.79%1 Month Performance6.31%7.74%5.22%1.51%1 Year Performance75.25%18.08%31.92%25.40% Genelux Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)GNLXGenelux1.5199 of 5 stars$3.54-0.6%$17.75+401.4%+76.2%$133.71M$10K-4.1210News CoveragePositive NewsAnalyst RevisionPRMEPrime Medicine3.5681 of 5 stars$3.51-7.4%$8.92+154.0%-15.8%$472.08M$4.96M-1.71234ARVNArvinas3.8756 of 5 stars$6.59+4.8%$19.76+199.9%-71.5%$461.80M$263.40M-6.52420ETONEton Pharmaceuticals2.6014 of 5 stars$17.05-0.5%$29.67+74.0%+322.8%$459.65M$39.01M-106.5620SVRASavara3.1288 of 5 stars$2.70+2.3%$5.60+107.4%-30.1%$456.29MN/A-5.6220News CoverageEarnings ReportAnalyst UpgradePVLAPalvella Therapeutics2.8699 of 5 stars$41.71+2.0%$52.40+25.6%N/A$452.18M$42.81M-3.45N/ANews CoverageEarnings ReportAnalyst ForecastITOSiTeos Therapeutics2.8019 of 5 stars$10.11flat$15.50+53.3%-32.3%$446.92M$35M-2.1690Positive NewsSNDLSNDL2.0186 of 5 stars$2.01+19.3%$4.00+99.5%-9.0%$441.46M$671.81M-7.432,516High Trading VolumeCGEMCullinan Therapeutics1.5293 of 5 stars$7.09-2.9%$30.00+323.1%-54.2%$430.95MN/A-2.2030Analyst ForecastCMPSCOMPASS Pathways2.677 of 5 stars$4.34-1.1%$16.29+275.2%-38.1%$421.18MN/A-2.36120KODKodiak Sciences3.1657 of 5 stars$8.03+1.6%$9.00+12.1%+327.9%$416.83MN/A-2.2190News CoverageEarnings ReportAnalyst Forecast Related Companies and Tools Related Companies Prime Medicine Alternatives Arvinas Alternatives Eton Pharmaceuticals Alternatives Savara Alternatives Palvella Therapeutics Alternatives iTeos Therapeutics Alternatives SNDL Alternatives Cullinan Therapeutics Alternatives COMPASS Pathways Alternatives Kodiak Sciences Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:GNLX) was last updated on 8/18/2025 by MarketBeat.com Staff From Our PartnersWhen the levee breaksThe U.S. Treasury just confirmed it plans to borrow $1.01 trillion this quarter—nearly double what was project...Porter & Company | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredThe stealth altcoin the financial world is underestimatingThis DeFi project could soar next When altcoin season fully kicks in—which the data suggests is happening R...Crypto 101 Media | SponsoredMusk’s Project Colossus could mint millionairesI predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new milliona...Brownstone Research | SponsoredThink you missed gold’s boom? Think againIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | SponsoredBut this $20 American company could control the secretThe "Impossible" Chip That Runs on Pure Light Google's quantum computer shocked the world... but China DEMO...The Oxford Club | SponsoredTax Drain Deadline: Protect Your Wealth Before September 15thOn September 15th, the IRS collects another round of quarterly tax payments—targeting self-employed profession...American Alternative | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Genelux Corporation Please log in to your account or sign up in order to add this asset to your watchlist. Share Genelux With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access